De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
The TCbHP×6 regimen is favored for individuals aged ≤ 50 years and those aged > 50, ≤60 years with HR-negative status or clinical stage T2-4. For patients in compromised general condition or lacking the specified indications, the THP×6 regimen emerges as a lower-toxicity alternative with satisfactory efficacy. To ensure treatment efficacy, a minimum of 6 cycles of neoadjuvant THP is required.
Authors
- Haibo Wang (ORCID: https://orcid.org/0000-0002-5585-704X)
- Li Bian (ORCID: https://orcid.org/0000-0001-9916-3720)
- Song Wu (ORCID: https://orcid.org/0000-0002-8907-4545)
- Zhigang Yu
- Zefei Jiang (ORCID: https://orcid.org/0000-0002-4295-0173)
- Shaohua Zhang
- Kun Wang (ORCID: https://orcid.org/0000-0003-2513-768X)
- Feng Li (ORCID: https://orcid.org/0000-0002-3314-7127)
- Jianbin Li
- Tao Wang (ORCID: https://orcid.org/0009-0003-1825-0163)
Institutions
- Qingdao University (CN)
- Chinese PLA General Hospital (CN)
- Second Hospital of Shandong University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1186/s12957-024-03468-5
- Citations
- 7
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- General Hospital of People’s Liberation Army